These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 17358025)

  • 1. Special issue on health risks of perinatal exposure to nucleoside reverse transcriptase inhibitors.
    Walker VE; Poirier MC
    Environ Mol Mutagen; 2007; 48(3-4):159-65. PubMed ID: 17358025
    [No Abstract]   [Full Text] [Related]  

  • 2. Does perinatal antiretroviral therapy create an iatrogenic cancer risk?
    Wogan GN
    Environ Mol Mutagen; 2007; 48(3-4):210-4. PubMed ID: 17358028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.
    Brogly SB; Ylitalo N; Mofenson LM; Oleske J; Van Dyke R; Crain MJ; Abzug MJ; Brady M; Jean-Philippe P; Hughes MD; Seage GR
    AIDS; 2007 May; 21(8):929-38. PubMed ID: 17457086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection.
    Nerad JL; Kessler HA
    Clin Infect Dis; 2001 Jun; 32(11):1635-6. PubMed ID: 11340537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection.
    Rabaud C; Bevilacqua S; Beguinot I; Dorvaux V; Schuhmacher H; May T; Canton P
    Clin Infect Dis; 2001 May; 32(10):1494-5. PubMed ID: 11317252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamivudine for the treatment of HIV.
    Kumar PN; Patel P
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):105-14. PubMed ID: 20001611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial and peroxisomal dysfunction following perinatal exposure to antiretroviral drugs.
    Stojanov S; Wintergerst U; Belohradsky BH; Rolinski B
    AIDS; 2000 Jul; 14(11):1669. PubMed ID: 10983660
    [No Abstract]   [Full Text] [Related]  

  • 8. HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV-infected patients.
    Quirino T; Niero F; Ricci E; Pusterla L; Carradori S; Gabbuti A; Iemoli E; Landonio S; Faggion I; Bonfanti P;
    Antivir Ther; 2000 Sep; 5(3):195-7. PubMed ID: 11075939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unrecognized near-fatal hyperlactatemia in an HIV-infected infant exposed to nucleoside reverse transcriptase inhibitors.
    Koh MT
    Int J Infect Dis; 2007 Jan; 11(1):85-6. PubMed ID: 16581278
    [No Abstract]   [Full Text] [Related]  

  • 10. Leukocytopenia due to zidovudine- and nevirapine-containing regimens in elderly patients with HIV infection.
    Yamamoto Y; Yasuoka A; Yasuoka C; Genka I; Teruya K; Kikuchi Y; Tachikawa N; Oka S
    Jpn J Infect Dis; 2000 Dec; 53(6):244-5. PubMed ID: 11227023
    [No Abstract]   [Full Text] [Related]  

  • 11. A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV.
    Nurutdinova D; Overton ET
    Expert Opin Drug Saf; 2009 Nov; 8(6):683-94. PubMed ID: 19715450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-nucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects.
    Bongiovanni M; Fausto A; Cicconi P; Aliprandi A; Cornalba G; Bini T; Sardanelli F; D'Arminio Monforte A
    J Antimicrob Chemother; 2006 Aug; 58(2):485-6. PubMed ID: 16751202
    [No Abstract]   [Full Text] [Related]  

  • 13. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors.
    Benhammou V; Warszawski J; Bellec S; Doz F; André N; Lacour B; Levine M; Bavoux F; Tubiana R; Mandelbrot L; Clavel J; Blanche S;
    AIDS; 2008 Oct; 22(16):2165-77. PubMed ID: 18832880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial dysfunction following perinatal exposure to nucleoside analogues.
    Blanche S; Tardieu M; Benhammou V; Warszawski J; Rustin P
    AIDS; 2006 Aug; 20(13):1685-90. PubMed ID: 16931932
    [No Abstract]   [Full Text] [Related]  

  • 15. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission.
    Giaquinto C; De Romeo A; Giacomet V; Rampon O; Ruga E; Burlina A; De Rossi A; Sturkenboom M; D'Elia R
    AIDS; 2001 May; 15(8):1074-5. PubMed ID: 11399997
    [No Abstract]   [Full Text] [Related]  

  • 16. Perinatal exposure to zidovudine--benefits and risks.
    Mofenson LM
    N Engl J Med; 2000 Sep; 343(11):803-5. PubMed ID: 10984571
    [No Abstract]   [Full Text] [Related]  

  • 17. Understanding the reverse transcriptase inhibitors in HIV.
    Edmonds-Ogbuokiri J
    Fac Notes (New Orleans La); 1998; 10(6):13-5. PubMed ID: 11366142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New fixed once daily combination as nucleoside backbone. Basis for long-term therapy success].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():66-8. PubMed ID: 16385881
    [No Abstract]   [Full Text] [Related]  

  • 19. Maternal antiretrovirals and hepatic enzyme, hematologic abnormalities among human immunodeficiency virus type 1-uninfected infants: the NISDI perinatal study.
    Mussi-Pinhata MM; Rego MA; Freimanis L; Kakehasi FM; Machado DM; Cardoso EM; Read JS;
    Pediatr Infect Dis J; 2007 Nov; 26(11):1032-7. PubMed ID: 17984811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered heterochromatin organization after perinatal exposure to zidovudine.
    Senda S; Blanche S; Costagliola D; Cibert C; Nigon F; Firtion G; Floch C; Parat S; Viegas-Péquignot E
    Antivir Ther; 2007; 12(2):179-87. PubMed ID: 17503660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.